What is Citius Oncology, Inc.'s interest coverage?

Citius Oncology, Inc. (CTOR) reported interest coverage of -146.6× in Q1 2026.

What does interest coverage mean?

Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.

Citius Oncology, Inc. CTOR Interest coverage

Interest coverage at other companies

Delcath SystemsDCTH

-0.1×—

Arcus BiosciencesRCUS

-39.8×-15.5×

ImmunityBio, Inc.IBRX

-5×-1.1×

Gilead SciencesGILD

10.3×+2.0×

United TherapeuticsUTHR

87.5×+48.2×

OmerosOMER

-5.8×-1.2×

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Calculated from Citius Oncology, Inc.’s reported figures.

ebit/interest expense=-146.6×

Based on trailing twelve months.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s interest coverage?: Citius Oncology, Inc. (CTOR) reported interest coverage of -146.6× in Q1 2026.
What does interest coverage mean?: Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.